La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Tasly Pharmaceutical Group Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jing Su

Amministratore delegato

CN¥2.7m

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Jul 22

Estimating The Intrinsic Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Jun 13

The Market Doesn't Like What It Sees From Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Yet

May 13

Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Apr 26

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Mar 15

AMMINISTRATORE DELEGATO

Jing Su (61 yo)

no data

Mandato

CN¥2,659,900

Compensazione

Mr. Jing Su is General Manager and Director of Tasly Pharmaceutical Group Co., Ltd.

Tasly Pharmaceutical Group Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Tasly Pharmaceutical Group Co., Ltd, Annual General Meeting, May 08, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 23% overvalued

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2024 Results on Aug 24, 2024

Price target increased by 8.7% to CN¥16.17

Estimating The Intrinsic Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Now 20% overvalued

Dividend of CN¥0.33 announced

The Market Doesn't Like What It Sees From Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Yet

First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 1Q 2023)

Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Price target decreased by 7.0% to CN¥13.88

Tasly Pharmaceutical Group Co., Ltd, Annual General Meeting, May 08, 2024

Now 21% undervalued after recent price drop

Tasly Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 16%

Now 22% undervalued after recent price drop

ShuYu Civilian Pharmacy Corp., Ltd. Scraps Plan to Buy Stake in Tasly Pharmaceutical's Two Units

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.047 in 3Q 2022)

Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2023 Results on Oct 28, 2023

Price target increased by 10% to CN¥12.76

Price target decreased by 13% to CN¥10.64

Consensus EPS estimates fall by 19%

Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.10 in 2Q 2022)

Now 21% undervalued after recent price drop

Consensus EPS estimates increase by 12%

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2023 Results on Aug 26, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued

Price target increased by 9.3% to CN¥12.10

Price target increased by 7.3% to CN¥11.79

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 8.0% to CN¥10.99

Consensus EPS estimates fall by 35%

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.047 (vs CN¥0.32 in 3Q 2021)

Price target decreased to CN¥10.19

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.45 in 2Q 2021)

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to CN¥14.34

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Price target increased to CN¥16.52

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall to CN¥1.03

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.27 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.26 in 2Q 2020)

Consensus revenue estimates fall to CN¥7.67b

First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.20 in 1Q 2020)

Tasly Pharmaceutical Group Co., Ltd to Report Fiscal Year 2020 Results on Mar 30, 2021

Tasly Pharmaceutical Group Co., Ltd(XSSC:600535) dropped from S&P Global BMI Index

New 90-day low: CN¥13.57

New 90-day low: CN¥14.49

Price target raised to CN¥19.43

New 90-day low: CN¥14.83

New 90-day low: CN¥16.61

Earnings beat expectations, revenue disappoints

New 90-day high - CN¥19.62

Earnings released

Chongqing Pharmaceutical (Group) Co., Ltd. completed the acquisition of Tianjin Tasly Medicine Distribution Group CO.,LTD. from a group of shareholders.

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020

AMMINISTRATORE DELEGATO

Mandato